The FHIT gene product: Tumor suppressor and genome "caretaker"

Cellular and Molecular Life Sciences

Volumn 71, Issue 23, 2014, Pages 4577-4587

  Waters, Catherine E ^a,b   Saldivar, Joshua C ^c   Hosseini, Seyed Ali ^d   Huebner, Kay ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Common fragile sites; FRA3B FHIT; Genome instability; Mutator phenotype; Replication stress

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR PROTEIN;

ALLELE; APOPTOSIS; CELL TRANSFORMATION; CELLS BY BODY ANATOMY; CHROMOSOMAL INSTABILITY; CHROMOSOME FRAGILE SITE; CHROMOSOME FRAGILITY; DNA DAMAGE; DNA STRAND BREAKAGE; EPITHELIAL MESENCHYMAL TRANSITION; FHIT GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE PRODUCT; GENOME; GENOMIC INSTABILITY; GENOTYPE; HUMAN; NONHUMAN; NUCLEOTIDE METABOLISM; PHENOTYPE; PRECANCER; PROTEIN EXPRESSION; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE; ANIMAL; CELL CYCLE; DNA REPLICATION; GENETICS; NEOPLASM; PATHOLOGY;

ACID ANHYDRIDE HYDROLASES; ANIMALS; CELL CYCLE; DNA DAMAGE; DNA REPLICATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84921936578     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1722-0     Document Type: Review

References (75)

1. Durkin SG, Glover TW (2007) Chromosome fragile sites. Annu Rev Genet 41:169-192
2. Yunis JJ, Soreng AL (1984) Constitutive fragile sites and cancer. Science 226:1199-1204
3. Letessier A, Millot GA, Koundrioukoff S, Lachagès AM, Vogt N, Hansen RS, Malfoy B, Brison O, Debatisse M (2011) Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 470:120-123
4. Hosseini SA, Horton S, Saldivar JC, Miuma S, Stampfer MR, Heerema NA, Huebner K (2013) Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability. Gene Chromosome Cancer 52(11):1017-1029
5. Le Tallec B, Millot GA, Blin ME, Brison O, Dutrillaux B, Debatisse M (2013) Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Rep 4(3):420-428
6. Saldivar JC, Shibata H, Huebner K (2010) Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem 109:858-865
7. Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H, Sun J, Wheeler LJ, Mathews CK, Huebner K (2012) Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet 8:e1003077
8. Miuma S, Saldivar JC, Karras JR, Waters CE, Paisie CA, Wang Y, Jin V, Sun J, Druck T, Zhang J, Huebner K (2013) Fhit deficiency-induced global genome instability promotes mutation and clonal expansion. PLoS ONE 8(11):e80730
9. Holbach LM, von Moller A, Decker C, Jünemann AG, Rummelt-Hofmann C, Ballhausen WG (2002) Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome. Am J Ophthalmol 134(1):147-148
10. Goldberg M, Rummelt C, Foja S, Holbach LM, Ballhausen WG (2006) Different genetic pathways in the development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients. Hum Mutat 27(2):155-162
11. Huebner K, Garrison PN, Barnes LD, Croce CM (1998) The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 32:7-31
12. Durkin SG, Ragland RL, Arlt MF, Mulle JG, Warren ST, Glover TW (2008) Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci USA 105:246-251
13. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K (2005) Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55:471-478
14. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW (1997) Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15:1653-1659
15. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti M et al (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58:5032-5037
16. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC et al (1997) Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862
17. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD et al (1997) Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57:3664-3668
18. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N, Kawasaki H (2001) Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61:205-211
19. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K, Huebner K, Croce CM (2000) Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60:1177-1182
20. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J (1999) Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 59:5270-5274
21. Butler D, Collins C, Mabruk M, Leader MB, Kay EW (2002) Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol Oncol 86:144-149
22. Yuge T, Nibu K, Kondo K, Shibahara J, Tayama N, Sugasawa M (2005) Loss of FHIT expression in squamous cell carcinoma and premalignant lesions of the larynx. Ann Otol Rhinol Laryngol 114:127-131
23. Luan X, Ramesh KH, Cannizzaro LA (1998) FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases. Cytogenet Cell Genet 81:183-188
24. Ozkara SK, Corakçi A (2005) FHIT expression in neoplastic, hyperplastic, and normal endometrium. Int J Gynecol Cancer 15:1081-1088
25. Velickovic M, Delahunt B, Grebe SK (1999) Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 59:1323-1326
26. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T et al (2000) Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97:4742-4747
27. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rüdiger T, McCue PA, Croce CM, Huebner K (2001) The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98:10250-10255
28. Huebner K, Croce CM (2001) FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 1:214-221
29. Okumura H, Ishii H, Pichiorri F, Croce CM, Mori M, Huebner K (2009) Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci 100:1145-1150
30. Pichiorri F, Okumura H, Nakamura T, Garrison PN, Gasparini P, Suh SS, Druck T, McCorkell KA, Barnes LD, Croce CM et al (2009) Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions. J Biol Chem 284:1040-1049
31. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M et al (2008) Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem 283:13736-13744
32. Rimessi A, Marchi S, Fotino C, Romagnoli A, Huebner K, Croce CM, Pinton P, Rizzuto R (2009) Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Natl Acad Sci USA 106:12753-12758
33. Jayachandran G, Sazaki J, Nishizaki M, Xu K, Girard L, Minna JD, Roth JA, Ji L (2007) Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res 67:10379-10388
34. Joannes A, Bonnomet A, Bindels S, Polette M, Gilles C, Burlet H, Cutrona J, Zahm JM, Birembaut P, Nawrocki-Raby B (2010) Fhit regulates invasion of lung tumor cells. Oncogene 29:1203-1213
35. Joannes A, Grelet S, Duca L, Gilles C, Kileztky C, Dalstein V, Birembaut P, Polette M, Nawrocki-Raby B (2014) Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Mol Cancer Res. doi: 10.1158/1541-7786.MCR-13-0386-T
36. Gaudio E, Paduano F, Spizzo R, Ngankeu A, Zanesi N, Gaspari M, Ortuso F, Lovat F, Rock J, Hill GA, Kaou M, Cuda G, Aqeilan RI, Alcaro S, Croce CM, Trapasso F (2013) Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel. PLoS ONE 8(11):e78610
37. Gardenswartz A, Aqeilan RI (2014) WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications. Exp Biol Med 239(3):253-263
38. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI (1998) An FHIT tumor suppressor gene? Genes Chromosome Cancer 21:281-289
39. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
40. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220-228
41. Zhu Y, McAvoy S, Kuhn R, Smith DI (2006) RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25:2901-2908
42. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352-1355
43. Aguilera A, Gómez-González B (2008) Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet 9:204-217
44. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307-315
45. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870
46. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B et al (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913
47. Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J et al (2012) Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J Exp Med 209:2215-2228
48. Dobrovolsky VN, McGarrity LJ, VonTungeln LS, Mittelstaedt RA, Morris SM, Beland FA, Heflich RH (2005) Micronucleated erythrocyte frequency in control and azidothymidine-treated Tk +/+, Tk ± and Tk-/- mice. Mutat Res 570:227-235
49. Holmberg C, Fleck O, Hansen HA, Liu C, Slaaby R, Carr AM, Nielsen O (2005) Ddb1 controls genome stability and meiosis in fission yeast. Genes Dev 19:853-862
50. Aird KM, Zhang R (2014) Nucleotide metabolism, oncogene-induced senescence and cancer, Cancer Letters (In press)
51. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R (2013) Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep 3(4):1252-1265
52. Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, Edgren H, Almusa H, Robyr D, Guipponi M, Saarela J et al (2012) A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res 72:6279-6289
53. Loeb LA (2011) Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 11:450-457
54. Loeb LA (2010) Mutator phenotype in cancer: origin and consequences. Semin Cancer Biol 20:279-280
55. Yates LR, Campbell PJ (2012) Evolution of the cancer genome. Nat Rev Genet 13:795-806
56. Bodmer W, Bielas JH, Beckman RA (2008) Genetic instability is not a requirement for tumor development. Cancer Res 68:3558-3560 (discussion 3560-3551)
57. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238-18242
58. Poli J, Tsaponina O, Crabbé L, Keszthelyi A, Pantesco V, Chabes A, Lengronne A, Pasero P (2012) dNTP pools determine fork progression and origin usage under replication stress. EMBO J 31:883-894
59. Davidson MB, Katou Y, Keszthelyi A, Sing TL, Xia T, Ou J, Vaisica JA, Thevakumaran N, Marjavaara L, Myers CL et al (2012) Endogenous DNA replication stress results in expansion of dNTP pools and a mutator phenotype. EMBO J 31:895-907
60. Iraqui I, Chekkal Y, Jmari N, Pietrobon V, Fréon K, Costes A, Lambert SA (2012) Recovery of arrested replication forks by homologous recombination is error-prone. PLoS Genet 8:e1002976
61. Villarreal DD, Lee K, Deem A, Shim EY, Malkova A, Lee SE (2012) Microhomology directs diverse DNA break repair pathways and chromosomal translocations. PLoS Genet 8:e1003026
62. Deem A, Keszthelyi A, Blackgrove T, Vayl A, Coffey B, Mathur R, Chabes A, Malkova A (2011) Break-induced replication is highly inaccurate. PLoS Biol 9:e1000594
63. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, Klimczak LJ, Kryukov GV, Malc E, Mieczkowski PA et al (2012) Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 46:424-435
64. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993
65. Courtois-Cox S, Jones SL, Cichowski K (2008) Many roads lead to oncogene-induced senescence. Oncogene 27:2801-2809
66. Nicholson JM, Duesberg P (2009) On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet 194:96-110
67. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9:493-505
68. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ et al (2012) Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44:651-658
69. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, Ling H, Hetrick KN, Pugh EW, Amos C et al (2012) Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 44:642-650
70. Young MA, Larson DE, Sun CW, George DR, Ding L, Miller CA, Lin L, Pawlik KM, Chen K, Fan X et al (2012) Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell 10:570-582
71. Torres-Rosell J, De Piccoli G, Cordon-Preciado V, Farmer S, Jarmuz A, Machin F, Pasero P, Lisby M, Haber JE, Aragón L (2007) Anaphase onset before complete DNA replication with intact checkpoint responses. Science 315:1411-1415
72. Sutherland GR (1979) Heritable fragile sites on human chromosomes I. Factors affecting expression in lymphocyte culture. Am J Hum Genet 31:125-135
73. Blount BC, Ames BN (1995) DNA damage in folate deficiency. Baillieres Clin Haematol 8:461-478
74. MacGregor JT, Schlegel R, Wehr CM, Alperin P, Ames BN (1990) Cytogenetic damage induced by folate deficiency in mice is enhanced by caffeine. Proc Natl Acad Sci USA 87:9962-9965
75. Rampersaud GC, Bailey LB, Kauwell GP (2002) Relationship of folate to colorectal and cervical cancer: review and recommendations for practitioners. J Am Diet Assoc 102:1273-1282